Trastuzumab containing regimens for early breast cancer
References
Additional references
Apolone G, Joppi R, Bertele V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer 2005;93(5):504‐9.
Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al. Correlation of quality measures with estimates of treatment effect in meta‐analyses of randomized controlled trials. JAMA 2002;287(22):2973‐82.
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti‐p185HER2 monoclonal antibody in patients with HER2/neu‐overexpressing metastatic breast cancer. Journal of Clinical Oncology 1996;14(3):737‐44.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti‐HER2 monoclonal antibody in women who have HER2‐overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 1999;17(9):2639‐48.
Coussens L, Yang‐Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230(4730):1132‐9.
Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non‐randomised intervention studies. Health Technology Assessment 2003;7(27):iii‐x, 1‐173.
Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. In: The Cochrane Library Issue 2, 2006.. Chichester, UK: John Wiley & Sons, Ltd., 2006.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88.
Egger M, Davey Smith G, Schneider M. Systematic reviews of observational studies. Systematic reviews in health care: meta‐analysis in context. 2001:211‐27.
U.S. Food and Drug Administration. FDA Oncology Tools Approval Summary for Trastuzumab for HERCEPTIN. http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=284 (accessed 9 Feb 2006).
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6.
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9.
Loke YK, Price D, Herxheimer A. Including adverse effects. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 6b. In: The Cochrane Library Issue 2, 2006.. Chichester, UK: John Wiley & Sons, Ltd, 2006.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13.
NICE. Breast cancer ‐ trastuzumab (No. 34). http://www.nice.org.uk/page.aspx?o=29274 (accessed 9 Feb 2006).
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Piccart‐Gebhart MJ, Procter M, Leyland‐Jones B, Goldhirsch A, Untch M, Smith I, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2‐positive breast cancer. New England Journal of Medicine 2005;353(16):1659‐72.
Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Controlled Clinical Trials 1997;18(6):530‐45.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2‐positive breast cancer. New England Journal of Medicine 2005;353(16):1673‐84.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12.
Shadish WR, Cook TD, Campbell DT. Statistical conclusion validity and internal validity. Experimental and quasi‐experimental designs for generalized causal inference. Boston New York: Houghton Mifflin Company, 2002.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER‐2/neu oncogene. Science 1987;235(4785):177‐82.
Tan‐Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, Shannon RP, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node‐positive, human epidermal growth factor receptor 2‐overexpressing breast cancer: NSABP B‐31. Journal of Clinical Oncology 2005;23(31):7811‐9.
The Lancet editorial. Herceptin and early breast cancer: a moment for caution. Lancet 2005;366(9498):1673.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First‐line Herceptin monotherapy in metastatic breast cancer. Oncology 2001;61 Suppl 2:37‐42.
| Cardiac toxicity |
| Left ventricular ejection fraction (LVEF) abnormal by multiple‐gated acquisition (MUGA) or echocardiogram |
| Uncontrolled arterial hypertension |
| Myocardial infarction |
| Unstable angina or angina pectoris |
| Congestive heart failure |
| Serious cardiac arrhythmia |
| QTc interval greater than 440 msec |
| Rhythm abnormalities requiring permanent therapy |
| Prolonged PR interval or atrioventricular block on electrocardiogram (ECG) |
| Second or third‐degree heart blocks |
| Peripheral vascular disease |
| Cardiomyopathy |
| Signs and symptoms of cardiac dysfunction (such as dyspnea, increased cough, paroxysmal nocturnal dyspnea, peripheral edema) |
| Other clinically significant cardiovascular disease |
Figures and Tables -
Table 1. Potential list of cardiac adverse events
